Our Team


David Steinberg, MBA
Co-founder and CEO

Mr. Steinberg is a General Partner at Longwood Fund and Chief Executive Officer and co-founder of Longwood portfolio company Pyxis Oncology. Previously, Mr. Steinberg was at PureTech Health, (LSE: PRTC), a biotech incubator which he co-founded and served as Chief Innovation Officer, focusing on venture creation, investing, and launching innovative biotech companies. Mr. Steinberg was the co-founder and CEO of several biotech companies, including Longwood-founded Pyxis Oncology, Vedanta Biosciences, Calix, Vor Biopharma, and was co-founder of Restorbio (NASDAQ: TORC). He previously worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and R&D at P&G Pharmaceuticals. He received his MBA in strategy and finance from the University of Chicago Booth School of Business and holds a BA in biology from Cornell University.

Aleks Radovic-Moreno, PhD
Co-founder and President

Dr. Radovic-Moreno is an Entrepreneur-in-Residence at Longwood Fund, where he is involved in building and supporting portfolio companies. He was previously Senior Vice President at PureTech Health (LSE: PRTC), where he was a co-founder and member of the senior leadership team of several portfolio companies.

Dr. Radovic-Moreno was a co-founder of Vor Biopharma, a company developing novel engineered hematopoietic stem cell therapies for treating blood cancers. At Vor, Dr. Radovic-Moreno led a fundraising effort that culminated in a $42M Series A financing led by 5AM Ventures & RA Capital in 2019. He also co-founded and acted as interim CEO of Alivio Therapeutics, a company focused on developing new therapies for autoimmune and inflammatory diseases based on a new category of inflammation-targeting drugs. He was previously a scientist at Exicure, where he was the lead inventor of AST-008, a TLR9 agonist now in phase 2 trials for treating various solid tumors.

Dr. Radovic-Moreno completed his graduate work as an NSF Fellow in Robert Langer's lab at MIT, where he developed novel strategies for managing bacterial infections, including a novel vaccine candidate for chlamydia infections. Dr. Radovic-Moreno was awarded the Alumni Achievement Award by the Pennsylvania State University for extraordinary professional accomplishment by graduates under the age of 35. Dr. Radovic-Moreno received his B.S. in Chemical Engineering from the Pennsylvania State University and PhD in Chemical and Biomedical Engineering from MIT and the Harvard-MIT Division of Health Sciences & Technology.

Lea Hachigian, PhD

Dr. Hachigian is a Principal at Longwood Fund. While in this role, she co-founded TScan Therapeutics and Immunitas Therapeutics, serving as the founding President in each case, and continues to hold director seats at each company. Dr. Hachigian works across all aspects of company creation, including leading financings, scientific strategy, business development, team building, and early operations. Together, companies she has co-founded at Longwood Fund have raised nearly $100m in venture financing and have entered into collaborations with industry partners.

Dr. Hachigian received her Ph.D. from MIT in molecular and cellular neuroscience where she was a NSF Graduate Research Fellow. As a graduate student in the Heiman Lab at the Broad Institute, she studied the determinants of neuronal identity and vulnerability in disease. Prior to her doctorate, Dr. Hachigian received an A.B. from Harvard University where she graduated magna cum laude with highest honors in Neurobiology and received a certificate in Mind Brain and Behavior. While at Harvard, Dr. Hachigian researched genetic models of developmental disorders in the Fagiolini/Hensch lab at Children's Hospital/Harvard Medical School. She has received numerous fellowships for her research and multiple teaching awards for her work with both undergraduate and graduate students. Dr. Hachigian was named to the Forbes 30 Under 30 list for healthcare for her work in co-founding TScan Therapeutics.

Jason Rhodes, MBA

Jason Rhodes is a partner at Atlas Venture. Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO), Dyne Therapeutics (NASDAQ: DYN), and Disarm Therapeutics. He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics, and Accent Therapeutics.

Prior to joining Atlas Venture, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and charted the company’s strategic course from a private, research-stage company into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development.

Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Mersana Therapeutics (NASDAQ: MRSN), Ironwood Pharmaceuticals (NASDAQ: IRWD), and FoldRx (purchased by Pfizer).

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.

Josh Resnick, MD, MBA

Josh Resnick is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools.

Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital.

Dan Janney, MBA

Dan Janney is a Managing Director at Alta Partners, joining at its founding in 1996. He has nearly 25 years of successful early-stage investing experience in life sciences. Dan’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies.Prior to Alta, Dan was a senior investment banker at Montgomery Securities.


Dan is currently on the board of directors of several public and private companies, including Allakos (NASDAQ:ALLK), Curasen Therapeutics, Esperion Therapeutics (NASDAQ:ESPR), Krystal Biotech (NASDAQ:KYRS), Lassen Therapeutics, Novome Biotechnologies, and Prolacta Bioscience. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ:CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).


In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes, the Board of Directors of the California Academy of Sciences and serves on the Board of Regents of Georgetown University. He holds a B.A. from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.